ONCOSCIENCE BEGINS NIMOTUZUMAB TRIAL

Oncoscience has begun patient treatment for its Phase III trial of nimotuzumab in combination with radiation in children with diffuse, intrinsic pontine (brain stem) glioma. Three patients have been recruited.

The trial is a single-arm study in which 40 children with inoperable pontine glioma will be treated with radiation concomitant with nimotuzumab. The primary clinical endpoints in the trial will be progression-free survival with median survival as secondary endpoint.